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Abstract
Background: Tuberculous meningitis (TBM) is one of the common clinical manifestations of
extra-pulmonary tuberculosis. It is difficult to diagnose due to a lack of rapid, sensitive, and specific
tests. Newer methods, which are easy and reliable, are required to diagnose TBM at an early stage.
Thus our aim was to evaluate the polymerase chain reaction (PCR) technique, using primers
directed against the IS6110 gene, for the detection of Mycobacterium tuberculosis in the CSF, for the
diagnosis of TBM patients.
Methods: An in-house IS6110 PCR method using a specific pair of primers designed to amplify the
insertion sequence, IS6110, in the M. tuberculosis genome was used to analyze CSF. A total of 80
CSF samples from different groups of patients were studied (confirmed TBM n = 35, clinically
suspected TBM n = 16, non-TBM infectious meningitis n = 12, non infectious neurological diseases
n = 17).
Results: PCR gave a sensitivity of 91.4% and specificity of 75.9% for the diagnosis of TBM in
patients with TBM confirmed by culture. In 16 clinically diagnosed, but unconfirmed, TBM cases
PCR was positive in 10 (62.5%) cases. There were seven (24.1%) PCR-positive cases among the 29
patients with non-TBM and non-infectious neurological disease.
Conclusion: We conclude that the performance of an in-house IS6110 PCR assay is valuable in
the rapid diagnosis of tuberculous meningitis.
Background
Tuberculosis (TB) is one of the major causes of morbidity
and mortality worldwide. India has about 1.8 million new
cases of TB annually, accounting for a fifth of new cases in
the world – a greater number than in any other country
[1]. Among, extra-pulmonary TB, tuberculous meningitis
(TBM) leads to multiple central nervous system (CNS)
complications and remains a major health problem in
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underdeveloped and developing countries [2]. Delayed
treatment of TBM is associated with high mortality and
with neurological problems, which underscores the
importance for early diagnosis [3].
Confirming the clinical suspicion of TBM has always been
problematic. Acid-fast bacilli (AFB) staining of cerebrospi-
nal fluid (CSF) has a very low sensitivity [4]. Although
conventional bacterial culture is the gold standard for
diagnosis, the inherent time limitation of the culture-
based test, limits its value [5,6]. The culture of M. tubercu-
losis from CSF takes 4–6 weeks and leads to a delay in
diagnosis [7,8]. Analysis of CSF using antibody detection
is suggestive but not diagnostic of TBM [9]. In the absence
of any reliable diagnostic methods, various immunologi-
cal and molecular methods have been advocated includ-
ing ELISA [10] for demonstration of M. tuberculosis
antigen and antibodies, T cell based assay for IFN gamma
estimation (ELI SPOT), adenosine deaminase assay
[11,12], and polymerase chain reaction (PCR) [13,14].
However, all the above-mentioned methods are still being
evaluated.
Rapid techniques based on nucleic acid amplification
such asPCR have been reported to be more sensitive and
specific as they attempt to detect specific DNA sequences
from the organism under investigation. Several M. tuber-
culosis specific DNA sequences have been evaluated in dif-
ferent laboratories including MBP-64, 65 kDa antigen and
IS6110 [14]. The reliability of PCR depends on the ampli-
fication of DNA with primers specific for different target
sequences in the mycobacterial genome, and on optimal
DNA isolation and PCR procedures [15]. The observed
sensitivity and specificity of the PCR for M. tuberculosis in
clinical samples differs greatly among the different labora-
tories ranging from 50–90% and 60–100%, respectively
[6]. The repetitive nature of IS6110 insertion sequence in
M. tuberculosis genome makes it an attractive target for
PCR amplification, as it could contribute to a higher
degree of sensitivity of the assay [16,17]. Several studies
have been undertaken to evaluate the efficacy of IS6110
sequence for the diagnosis of tuberculosis [5,8,14]. In our
study, we describe our experience with the IS6110 based
PCR assay to detect M. tuberculosis DNA in CSF samples of
TBM and non-TBM cases in our Institute.
Methods
CSF samples from a total of 80 patients were analysed.
These consisted of confirmed and clinically suspected
TBM patients, n = 51, patients with other infections (pyo-
genic meningitis, n = 5, viral meningitis, n = 7), and con-
trol subjects with non-infectious neurological disorders, n
= 17. Patients for this study were admitted to the Neurol-
ogy Department of Central India Institute of Medical sci-
ences (CIIMS), Nagpur between September 2005 and
December 2006. All patients were above the age of 20
years and had given written consent for the study. CSF
samples for ADA estimations and other tests were
obtained before starting any specific treatment in all cases
of neurological disorders including viral, bacterial, and
mycobacterial meningitis. The Institutional Ethics Com-
mittee of Central India Institute of Medical Sciences, Nag-
pur, approved the study. To establish a diagnosis of
meningitis, 2–5 ml of CSF was withdrawn from patients
using a lumbar puncture. CSF was then subjected to rou-
tine biochemical and pathological analysis including
Gram, India ink, and AFB staining and culturing. Diagno-
sis of TBM and non-TBM was based on criteria described
below.
Patient groups
1. Tuberculous meningitis patients (n = 51)
A: Clinically confirmed cases (n = 35): Confirmed by the
presence of M. tuberculosis in CSF by staining and/or cul-
ture.
B: Clinically suspected patients (n = 16): This group had
negative cultures with all of the following observations:
a: Sub-acute or chronic fever with features of meningeal
irritation such as headache, neck stiffness and vomiting,
with or without other features of CNS involvement.
b: CSF samples showing raised protein levels, and/or
decreased glucose (CSF: blood glucose ratio < 0.5), and/or
pleocytosis with lymphocytic predominance.
c: Good clinical response to anti-tuberculous drugs.
2. Non-TBM patients
A) Non-TBM infectious meningitis (n = 12)
A: Pyogenic meningitis (n = 5):
Confirmed cases (n = 2): Presence of pathogenic bacteria
in CSF by staining and/or culture.
Clinically suspected (n = 3): This group included the cul-
ture negative cases with all of the following observations:
a: Fever and/or signs of meningeal irritation (patients who
have undergone cranial surgery to treat tumor(s), stroke,
or head injury and who have received antibiotics), or high
fever and/or signs of meningeal irritation with or without
CNS manifestations (patients who received broad-spec-
trum antibiotics).
b: CSF findings showing increased proteins, decreased
glucose (CSF: blood glucose ratio < 0.2), and/or pleocyto-
sis with a predominance of polymorphonuclear cells.Cerebrospinal Fluid Research 2007, 4:10 http://www.cerebrospinalfluidresearch.com/content/4/1/10
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c: Good clinical response to road-spectrum antibiotics.
B: Viral meningitis patients (n = 7): This group included
suspected patients with the following observations:
a: Acute onset of fever and symptoms and signs of menin-
geal irritation.
b: CSF samples showing mild increase in protein, glucose
levels often normal, and pleocytosis, predominantly lym-
phocytic.
c: No clinical evidence for extra cranial tuberculosis.
B) Non-infectious neurological disorders group (n = 17)
All other patients who had no evidence of CNS or extra
CNS bacterial or viral infections were grouped in the non-
infectious/control group. Patients included in this group
had chronic headache and hypertension n = 10, head
injury n = 2, paraparesis, dementia, myelopathy, acute cer-
ebellitis, and epilepsy, n = 1 each.
Culture procedure
CSF samples (0.5 ml) were inoculated into 5 ml BioFM
liquid media (Biorad, Marnes-la-Coquette, France) and
incubated at 37°C. All culture samples were examined
twice a week for 6 weeks. The positivity of culture was
defined by the growth of mycobacteria in the liquid
media.
DNA extraction
DNA was extracted according to the CTAB-phenol chloro-
form extraction method. Briefly, 0.2 ml of CSF was centri-
fuged at 10,000 rpm for 10 min. The supernatant was
discarded and the pellet suspended in 567 μl of TE buffer
(Tris EDTA, pH 7.4), 30 μl 10% SDS and 3 μl proteinase
K (20 mg/ml), mixed and incubated at 37°C for 1 h. After
incubation, 100 μl of 5 M NaCl and 80 μl of high-salt
CTAB buffer (containing 4 M NaCl, 1.8% CTAB (cetyl-tri-
methyl-ammonium bromide) was added and mixed fol-
lowed by incubation at 65°C for 10 min. An approximate
equal volume (0.7–0.8 μl) of chloroform-isoamyl alcohol
(24:1) was added, mixed thoroughly and centrifuged for
4–5 min in a microcentrifuge at 12,000 rpm. The aqueous
viscous supernatant was carefully decanted and trans-
ferred to a new tube. An equal volume of phenol: chloro-
form-isoamyl alcohol (1:1) was added followed by a 5
min spin at 12,000 rpm. The supernatant was separated
and then mixed with 0.6 volume of isopropanol to get a
precipitate. The precipitated nucleic acids were washed
with 75% ethanol, dried and re-suspended in 100 μl of TE
buffer.
Polymerase chain reaction (PCR)
In each independent PCR assay, test results were com-
pared with the results for one positive and one negative
control. The positive controls included the DNA of H37Rv
strain provided by Colorado State University, Fort Collins,
USA, (Contract No 1-A1-40091). Negative control
included PCR grade water.
Identification of M. tuberculosis was done using a specific
pair of primers designed to amplify an insertion sequence
IS6110 in the M. tuberculosis complex and the expected
band size was about123-bp. The sequence of these prim-
ers, T4 and T5, are: 5'-CCT GCG AGC GTA GGC GTC GG
3' and 5' CTC GTC CAG CGC CGC TTC GG 3' respec-
tively. A 50 μl reaction contained 10× assay buffer (Banga-
lore Genei, Bangalore, India), 10 mM dNTP's (Bangalore
Genei), 10 pmole of each primer (SIGMA-GENOSYS,
USA), 2.5 units Taq DNA Polymerase (Bangalore Genei)
and 5 μl of extracted DNA. Amplification was carried out
in a thermal minicycler (peqlab Biotechnologie GmbH,
Erlangen, Germany), which involved 40 cycles of denatur-
ation at 94°C for 2 min, annealing of primers at 68°C for
2 min, and primer extension at 72°C for 1 min. The
amplification products were separated on 2% agarose
gels, visualized on a UV- light transilluminator (Biotech R
& D Laboratories, Yercud, Salem, India) and photo-
graphed.
Results
Figure 1 shows the electrophoresis product of the 123 bp
amplification of IS6110  sequence of M. tuberculosis by
Amplification of the 123 bp product of M. tuberculosis by PCR Figure 1
Amplification of the 123 bp product of M. tuberculosis by 
PCR. PCR products were analyzed by electrophoresis on 2% 
agarose gel. M represents 100 bp DNA ladder. L1: positive 
control DNA (M. tuberculosis strain H37Rv). L2, L4, L6: clini-
cally positive TBM samples. L3, L5: non-TBM samples. L7: 
negative control.
100bp
M L 1 L 2L 3L 4L 5L 6 L 7
123bpCerebrospinal Fluid Research 2007, 4:10 http://www.cerebrospinalfluidresearch.com/content/4/1/10
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PCR. M represents 100 bp DNA ladder. Lane 1 (L1) repre-
sents the positive control DNA (M. tuberculosis strain
H37Rv). L2, L4, L6 show clinically positive TBM samples,
and L3 and L5 represent non-TBM samples. L7 is a nega-
tive control.
The results of the IS6110 PCR assay in the TBM and non-
TBM CSF samples are shown in Table 1. The IS6110 PCR
assay was positive in 91.4% (32/35) of confirmed TBM
cases. However, in the clinically diagnosed TBM patients,
but not confirmed by culture, the sensitivity of IS6110
PCR assay was 62.5% (10/16) (Table 1). Using culture as
the gold standard, the PCR assay showed a sensitivity of
91.4% and specificity of 75.9% with a positive predictive
value (PPV) = 85.7% and negative predictive value (NPV)
= 71.9%). The overall sensitivity and specificity (including
the TBM confirmed and clinically suspected cases
together) of PCR was thus found to be 82.4% (NPV =
71.9%) and 75.9% (PPV = 85.7%) respectively.
In the non-TBM infectious control group, PCR was posi-
tive in 3 samples (2 viral meningitis and 1 pyogenic men-
ingitis). In non-infectious control group PCR was found
to be positive in 4 samples (2 chronic headache, and 1
each of epilepsy and acute inflammatory demyelinating
myelitis, Table 1).
We have also compared our PCR data with the culture
results, which showed a sensitivity of 68.6% (NPV =
79.3%) and a specificity of 79.3% (PPV = 85.3%) as com-
pared to PCR showing 82.4% sensitivity (NPV = 71%) and
75.9% specificity (PPV = 85.7%), (Table 2).
Discussion
TBM is one of the common clinical manifestations of
extra-pulmonary tuberculosis. There has been a rising
trend of TBM in developing countries like India in the past
two decades. The detection of TBM is difficult to establish
because of its pleomorphic clinical presentation and vari-
able CSF cellular content and biochemical parameters,
similar to that of partially treated pyogenic meningitis
cases. Delayed diagnosis and treatment may be associated
with many serious CNS complications [18]. Hence, rapid
detection of M. tuberculosis is of vital importance for the
proper diagnosis and management of tuberculous menin-
gitis. Polymerase chain reaction is considered to be one of
the most specific diagnostic methods amid the many
rapid methods studied. PCR is the method of choice for
the diagnosis of tuberculosis in cases where the suspicion
is high but AFB staining is negative [19]. Many investiga-
tors have described the rapid detection of M. tuberculosis
by PCR, and have reported a high degree of sensitivity
using this method [20-24]. Although, IS6110 PCR is not a
novel diagnostic tool, it is believed that more studies are
required to establish its utility in the diagnosis of TBM
[20]. This study was planned to evaluate the efficacy of an
in-house IS6110 PCR assay to detect M. tuberculosis DNA
in CSF samples collected in our Institute.
The characteristic of the IS6110 PCR assay is that it should
be capable of detecting the presence of M. tuberculosis
DNA in all the samples proven to be TBM positive using
culture as the gold standard [20]. The present study was
performed blinded to evaluate the IS6110 PCR assay for
detection of M. tuberculosis in CSF samples available from
our hospital, using an in-house protocol. In our study, the
IS6110 PCR assay detected the presence of M. tuberculosis
DNA in 91.4% (32/35) cases of confirmed TBM and in
62.5% (10/16) cases of clinically diagnosed TBM which
were negative for mycobacterial culture, but had a clinical
index of suspicion for TBM.
Our results show agreement with some previous studies,
which showed 85–98% sensitivity [20,25,26] and a dis-
parity to various other studies, which had a low sensitivity
of 32–75% [27-30]. Rafi etal used a DNA extraction pro-
tocol involving CTAB detergent, which enhances PCR pos-
itivity in CSF samples [20]. We have also used the same
detergent along with the phenol-chloroform method for
DNA extraction. The reason for lower sensitivity in many
studies is unclear. However, it could be due to the low vol-
ume of CSF available, inefficient lysis of cells and/or loss
of DNA during purification or different methods used for
extraction of DNA [6]. In our study, the reason for PCR
negativity in six out of 16 clinically diagnosed TBM cases
could be the presence of a low number of bacteria or poor
lysis of bacteria, or possibly the presence of some PCR
inhibitors like bacterial contaminants, phenol etc. in the
CSF samples. Sometimes the tough cell wall of M. tubercu-
losis makes the isolation of target DNA difficult [30]. There
have been a few reports citing the existence of mycobacte-
rial strains that lack IS6110 element and therefore, infec-
tion with an IS6110 negative strain cannot be ruled out
[30-33]. Other sequences such as Ag85, MPB-64, 65 kDa,
Table 1: Numbers and percentages of patients showing positive 
or negative PCR in CSF samples.
Category PCR +ve PCR -ve
A] TBM (51) 42 (82.4%)
(i) Confirmed TBM * (35) 32 (91.4%) 3
(ii) Clinically diagnosed TBM ** (16) 10 (62.5%) 6
B] Non TBM (29) 7 (24.1%)
(i) Infectious # (12) 3 (25.0%) 9
(ii) Non-infectious## (17) 4 (23.5%) 13
*Confirmed TBM = culture +ve/smear -ve
**Clinical diagnosed TBM = culture -ve/smear -ve
#Pyogenic meningitis (5), viral meningitis (7)
## Chronic headache & hypertension (10), head injury (3), paraparesis, 
dementia, myelopathy, acute cerebellitis (1 each)Cerebrospinal Fluid Research 2007, 4:10 http://www.cerebrospinalfluidresearch.com/content/4/1/10
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and 38 kDa have also been used as target for PCR ampli-
fication. But IS6110 PCR has shown enhanced sensitivity
and specificity as a single step PCR assay [14,34]. Nested
PCR assay for diagnosis of TBM has provided a considera-
ble increase in sensitivity and specificity of DNA amplifi-
cation compared to conventional single-step PCR assay
[35,36]. However, the nested PCR assay using CSF sam-
ples has yet to be widely used in TBM diagnosis, due to its
laborious and time-consuming procedure, which carries a
high risk of sample contamination [36,37].
For the detection of overall TBM cases, the IS6110 PCR
assay was useful in terms of sensitivity (82.4%) and spe-
cificity (75.9%) as compared to culture results showing
68.6% sensitivity and 79.3% specificity in overall TBM
and non-TBM cases (Table 2). Therefore, it has been
found that IS6110 PCR is a good supportive method for
rapid diagnosis of clinically diagnosed TBM, particularly
where AFB staining and cultures are negative. Some other
studies have also suggested that CSF PCR for M. tuberculo-
sis is more sensitive than AFB staining and culture in cases
of clinically suspected TBM that responded to empirical
treatment [38].
Although the PCR can amplify the specific DNA sequence
by thousands of times within a few hours, the exquisite
specificity of PCR is also its main potential drawback. Out
of 29 non-TBM cases, PCR was positive in 3 cases of infec-
tious group (1 for pyogenic meningitis and 2 for viral
meningitis). In our study, the two PCR positive cases of
viral meningitis also had a positive TB culture, which sug-
gests they could be classified as case of mixed meningitis.
Mixed bacterial meningitis involving mycobacteria and
other bacteria have also been described earlier [39].
PCR was also positive in four cases of non-infectious non-
TBM group, which were actually diagnosed for chronic
headache (two cases), epilepsy and myelopathy myelitis
(one each). One reason for such false positive results
could be cross contamination with the amplified DNA
product in the laboratory. This is a well-recognized prob-
lem in other laboratories [40]. In spite of a small number
of CSF samples showing a positive result in the control
groups, the PCR assay was allied with a specificity of
75.9%.
Despite the improved sensitivity and specificity of PCR
technique, AFB and culture remain an important tech-
nique for diagnosing TBM. In this study, if the PCR
method had been accepted as the only diagnostic criteria,
it would have missed three culture confirmed cases.
In a meta-analysis of in-house and commercial protocols
used in the diagnosis of TBM, the results revealed that
commercial tests had an increased specificity but low sen-
sitivity (56%). This was in stark comparison to the sub-
stantial variability of the test results seen whenever an in-
house protocol was used [41]. Also the high cost involved
for commercial assays make it a significant drawback,
especially in developing countries like India. In such set-
tings, the role of an in-house assay turns out to be useful
in aiding the clinician towards a diagnosis of TBM, with a
reliable degree of specificity and sensitivity.
Conclusion
Our study made it evident that in-house IS6110 PCR is a
rapid and cost-effective diagnostic test for TBM that shows
good sensitivity and specificity. This can be adopted as a
method of choice for the diagnosis of mycobacterial infec-
tions in cases where suspicion is high, in combination
with other clinical criteria.
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